In equine and companion-animal oral solid-dosage manufacture, the dried Belladonnae Herba extract is controlled to 0.28–0.32% w/w total tropane alkaloids calculated as hyoscyamine by Ph. Eur. 2.2.20. Blending for tablets and capsules is confined to direct compression or dry granulation, because wet massing initiates ester hydrolysis of hyoscyamine to tropine and tropic acid at 40–50 °C. A typical tablet blend uses 5–15% w/w pregelatinised starch and silicified microcrystalline cellulose as filler; the active component is introduced by geometric dilution with an equal mass of coarse lactose monohydrate before transfer to a tumble blender. Final blend uniformity is verified by Ph. Eur. 2.9.40, with an acceptance value not exceeding 15.0. Tablets are compressed to 60–90 N breaking force; capping and edge loss appear above 110 N unless a non-hygroscopic binder is added. Magnesium stearate is held at 0.5% w/w and blended for not more than 5 min after the other excipients, because overlubrication increases disintegration beyond 15 min when tested by Ph. Eur. 2.9.1. The finished tablet or capsule product is packed in HDPE with silica-gel desiccant; moisture uptake above 3.0% w/w causes extract agglomeration and a measurable drop in content uniformity. Typical labelled strengths for veterinary oral solids are 0.1–0.25 mg total alkaloid per unit.

What Limits Terminal Steam Sterilisation of Belladonnae Herba Extract Injection?

For parenteral preanaesthetic solutions, unprocessed Belladonnae Herba powder is not used; the herb is extracted and purified to a total tropane alkaloid fraction with an atropine-equivalent potency. The injection is buffered with citrate to pH 3.0–3.5 because tropane esters hydrolyse measurably in aqueous phosphate above pH 4.5. Steam sterilisation at 121 °C for 15 min is feasible only in the citrate window; at pH 5.0, the same autoclave cycle produces 3–5% total alkaloid loss and increases tropic acid to detectable levels. Nitrogen overlay in Type I amber glass ampoules reduces oxidative discoloration but does not arrest hydroxide-catalysed hydrolysis. The solution is adjusted to isotonicity with 0.9% w/v sodium chloride, passed through a 0.22 µm PVDF membrane, and filled under nitrogen with a fill volume tolerance of ±1.0%. For products containing the scopolamine component, aseptic filtration is preferred over terminal steam sterilisation because the epoxy-bearing scopolamine degradant appears at lower temperatures than hyoscyamine degradation. Endotoxin is controlled to 0.5 EU/mg of total alkaloid, and elemental impurities are assessed against ICH Q3D. The injectable product is administered intramuscularly or subcutaneously in dogs at 0.02–0.04 mg/kg atropine-equivalent dose as preanaesthetic anticholinergic; equine protocols adjust dosing to vagal tone during induction with dissociative anaesthetics. Published data for this specific belladonna total alkaloid extract in steam-sterilised ampoules are limited; degradation kinetics are generally modelled from purified atropine sulfate solutions and may overestimate the stability of the crude pharmaceutical extract.

For equine oral top-dress powders and granulated premises, the extract is pre-dispersed onto a coarse lactose monohydrate carrier at 0.05–0.10% w/w total alkaloid. Particle-size mismatch between extract particles below 100 µm and carrier particles above 250 µm creates segregation in ordinary drum blenders; the extract is therefore geometrically diluted against an equal mass of carrier and passed through a 0.8 mm oscillating sieve before tumble blending at 12 rpm for 15 min in a twin-shell blender filled to 60%. When a granulated premix is specified, roller compaction is used instead of aqueous granulation; compacted ribbons are milled to 500–850 µm granules to avoid tropane ester hydrolysis. The terminal top-dress contains 0.1–0.2 mg total alkaloid per 20 g dose and is labelled for horses not intended for human consumption. Food-producing species require confirmation of a current maximum residue limit; in the absence of an MRL, use is not permitted in animals producing meat, milk, or eggs.

Oral Solution pH Drift and Preservative Efficacy in Multi-Dose Drops

Multi-dose oral solutions are compounded at 1.0 mg/mL total alkaloid as hyoscyamine in a citrate-sorbitol buffer at pH 4.0. The tropane ester bonds are stable below pH 5.0; a drift of +0.3 pH units over 24 months at 25 °C reduces scopolamine assay by 2–4% and is detected by Ph. Eur. 2.2.20 titration or a stability-indicating HPLC method. Sodium metabisulfite at 0.1% w/v suppresses oxidation, but its reaction product with benzalkonium chloride above 0.02% w/v creates turbidity and should be avoided. When preserved multi-dose packaging is required, benzalkonium chloride is limited to 0.01–0.02% w/v and challenged by Ph. Eur. 5.1.3; the solution must pass criterion A for bacteria and fungi. Hydroxyethylcellulose is added to achieve a viscosity of 2–5 mPa·s at 20 °C for dropper dose accuracy; above 15 mPa·s, foaming during filling reduces volumetric precision and entrains oxygen. The terminal product is filled into amber PET bottles with tamper-evident LDPE droppers and a calibrated dropper orifice delivering 0.05 mL per drop. Microbiological quality of the non-sterile liquid is controlled by Ph. Eur. 5.1.4; unopened samples are stored upright at 25 °C and 60% RH for long-term stability, with the label restricting use to horses and companion animals.

Ophthalmic aseptic solutions for equine uveitis are prepared at 0.5 mg/mL total alkaloid in a phosphate-citrate buffer at pH 3.8–4.2, adjusted to 280–320 mOsmol/kg with mannitol. Batches above pH 4.5 degrade during 121 °C for 15 min autoclaving, while batches below pH 3.5 produce conjunctival irritation; sterilising-grade filtration through 0.22 µm PVDF and aseptic filling into opaque LDPE bottles are therefore selected. The peristaltic pump is run at 120–150 rpm to reduce tubing spallation; fill volume RSD is held ≤2.0%. Sterility is tested by Ph. Eur. 2.6.1, subvisible particles by Ph. Eur. 2.9.19. A multidose preservative system must be re-validated because benzalkonium chloride at 0.01% w/v may bind to residual plant extract colloids; published data for this specific belladonna extract ophthalmic configuration are limited.

When Tamping Pin Capsule Machines Encounter High-Potency Tropane Alkaloid Blends

Capsule filling of Belladonnae Herba extract uses a granulation-free dry blend with a bulk density of 0.45–0.60 g/cm³ and a Carr compressibility index ≤20%; this range is necessary because a tamping pin machine derives fill weight from the compacted plug mass in each die. For a size 3 hard gelatin capsule containing 0.1 mg total alkaloid, the pin height is set at 2–3 mm and the powder bed height at 30–40 mm; under these settings, fill weight RSD is maintained at ≤3.0%. Static charge on hard gelatin capsules becomes severe below 35% RH, pulling fine extract particles onto the bushings and reducing net fill weight. The room humidity is therefore controlled at 45–50% RH, not lower; above 60% RH, the extract agglomerates and the powder bed collapses, causing content uniformity drift. Magnesium stearate is sprayed onto the die table at 0.25% w/w maximum, because higher concentrations transfer to the formed plug surface and delay capsule disintegration beyond 15 min when measured by Ph. Eur. 2.9.1. The filled capsules are sealed in a cold-form blister with desiccant, and weight variability is re-qualified after any change in pin shape, tamping station number, or powder bed height. Published data for this specific high-potency belladonna capsule configuration are limited; therefore, batch-to-batch variance in the dry extract particle size distribution should be monitored against a physical specification of D90 ≤150 µm to avoid shifts in plug compressibility that do not appear in alkaloid assay alone.